Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MWTX-05
- Development stage
- Preclinical
- Lead developer
- Mabwell Therapeutics
01
Overview
MWTX-05 is a first-in-class biotherapeutic being developed by Mabwell Therapeutics for the treatment of a specific subtype of congenital myasthenic syndrome (CMS). The drug leverages Mabwell's proprietary MyoDock™ neuromuscular junction (NMJ)-targeted delivery platform, which enables direct delivery and concentration of the therapeutic at the NMJ. This precision-targeting approach is designed to increase local drug exposure, enhance efficacy, and reduce off-target side effects typically associated with conventional systemic administration. The program is currently in the discovery phase, with lead candidates identified and being evaluated for efficacy in animal models. The specific molecular target and active ingredient have not been publicly disclosed.
Beyond the preview
Go deeper on MWTX-05.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MWTX-05.